Open Access<p>Phillygenin, a MELK Inhibitor, Inhibits Cell Survival and Epithelial–Mesenchymal Transition in Pancreatic Cancer Cells</p>
Author(s) -
Hongchun Li,
Miao Chen,
Zhuying Yang,
Qinxian Wang,
Jiesheng Wang,
Jin Dong,
Xiuyun Yang,
Fuxing Chen,
Xiumin Zhou,
Kexue Luo
Publication year - 2020
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s238958
Subject(s) - epithelial–mesenchymal transition , cancer research , pancreatic cancer , mesenchymal stem cell , medicine , cell , chemistry , cancer , pathology , metastasis , biochemistry
Pancreatic cancer (PC) is one of the leading causes of cancer, with the lowest 5-year survival rate of all cancer types. Given the fast metastasis of PC and its resistance to surgery, radiotherapy, chemotherapy, and combinations thereof, it is imperative to develop more effective anti-PC drugs. Phillygenin (PHI) has been reported to exert anti-cancer, anti-bacterial, and anti-inflammatory properties. However, the mechanism of PHI in the development of PC is still unclear.